OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	158
CAR T-cell therapy comes of age: Introductory editorial for the special issue	67
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	45
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	37
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	37
Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions	35
Updates on current and future research in acute myeloid leukemia	32
How to set up a clinical research center in Brazil, as an example of a middle-income country	28
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	23
Lessons learned from the Eµ-TCL1 mouse model of CLL	22
Epidemiology and etiology of diffuse large B-cell lymphoma	22
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	21
The role of viruses in HIV-associated lymphomas	21
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	19
TET2 mutation as prototypic clonal hematopoiesis lesion	18
More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?	18
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms	18
Antibody and immunotherapy in diffuse large B-cell lymphoma	18
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	17
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	17
The molecular map of CLL and Richter's syndrome	15
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	14
Roadmap for developing MRD as an early endpoint for drug approval in lymphoma	14
Developing MRD as an early endpoint for accelerated approval in CLL	14
Vaccinations in patients with chronic lymphocytic leukemia	14

T-cell engaging antibodies for B-cell lymphomas	14
Clonal hematopoiesis	13
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	13
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?	12
Cellular and immunotherapies for myelodysplastic syndromes	12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	12
outside front cover, PMS 8883 metallic AND 4/C	12
outside front cover, PMS 8883 metallic AND 4/C	11
Challenges and opportunities of CAR T-cell therapies for CLL	11
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	11
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	10
The biology of classical Hodgkin lymphoma	10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	10
Engineering the Next Generation of Antibody Therapeutics in Hematology	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
outside front cover, PMS 8883 metallic AND 4/C	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis	9
Menin inhibition for the treatment of acute leukemia	8
Blood-based MRD testing in multiple myeloma: Update on mass spectrometry methods for detecting the monoclonal immunoglobulin	8
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	8
The pediatric approach to Hodgkin lymphoma	8
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	8
Understanding MDS stem cells: Advances and limitations	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development	8
Clinical applications of circulating tumor DNA in central nervous system lymphoma	8
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	7
The crossroads of cancer therapies and clonal hematopoiesis	7
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	7
MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs	7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology	7
outside front cover, PMS 8883 metallic AND 4/C	7
DLBCL arising from indolent lymphomas: How are they different?	7
Diagnosis and management of hematologic malignancies in the context of telomere biology disorders	6
outside front cover, PMS 8883 metallic AND 4/C	6
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management	6
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
Measurable residual disease after CAR T-cell therapy	6
miRNA Biology in Chronic Lymphocytic Leukemia	6
License for a CAR T: Examining patient eligibility	6
Clonal hematopoiesis in telomere biology disorders	6
Alloimmunization in sickle cell disease: Addressing an ongoing clinical challenge	6
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	6
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	6
Bone marrow failure in telomere biology disorders: Current understanding and the emerging landscape of non-transplant therapies	5
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	5

Inflammation in myelodysplastic syndrome pathogenesis	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	5
table of contents (2 pages)	5
RNA splicing as a therapeutic target in myelodysplastic syndromes	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	5
Genetic aspects of telomere biology disorders	4
Closing the Disease Modification Gap: Emerging Therapies in Myelofibrosis Beyond JAK Inhibition	4
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	4
Minimal residual disease testing in hematologic malignancies: From early endpoint to precision clinical decision making	4
The case for prioritizing malignant hematology services in low- and middle-income countries	4
Tuning CAR T-cell therapies for efficacy and reduced toxicity	4
The paradox of HbSC disease—Not so benign after all	4
Rare somatic manifestations of telomere biology disorders	4
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	4
AML diagnostics in the 21st century: Use of AI	4
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
Role of the tumor microenvironment in CLL pathogenesis	4
Applications of virus-specific T cell therapies post-BMT	4
outside front cover, PMS 8883 metallic AND 4/C	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
Special issue on circulating tumor DNA: Introductory editorial	3
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics	3
Targeted immunoPET imaging of multiple myeloma	3
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	3
Tailoring intensive and less-intensive treatment in acute myeloid leukemia	3
outside front cover, PMS 8883 metallic AND 4/C	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
Solid malignancies in telomere biology disorders	3
outside front cover, PMS 8883 metallic AND 4/C	3
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
masthead	3
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape	3
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	3